This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.
Patients voluntarily enrolled in this study and signed informed consent forms;
Age 18-75 years;
Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;
MHC-II negative, with <5% tumour cells displaying staining <2+ (grade 2 or stronger);
Pregnant or lactating women, or women planning to become pregnant within 6 months prior to, during, or after the last dose of the investigational medicinal product.
Known signs of active bleeding from a lesion.
Patients with known dMMR/MSI-H status.
Oesophageal or pyloric near-obstruction affecting the subject's ability to eat or gastric emptying, or difficulty swallowing tablets.